Skip to contentN
Nutra Pharma Corp
N
NPHCNutra Pharma Corp Q3 2024 · 10-Q
Revenue$74.99K$74.99Kno prior Q3 2023 on file Net Income-$260.68K-$260.68KN/M vs Q3 2023 EPS Diluted$0.00$0.00— vs Q3 2023 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nutra Pharma Corp · CIK 1119643 · Engraved from SEC EDGAR
Operating Cash Flowderived$19,073N/M Margins · derivedGross margin94.3%
Operating margin-246.4%
Net margin-347.6%
ended Sep 30, 2024 · filed Jan 2, 2026 · 459 d after period end